This research compound features the cytotoxic payload MMAE, a potent tubulin inhibitor, conjugated via a cleavable DBCO-(PEG2-VC-PAB)2 linker. It is a key component for constructing antibody-drug conjugates (ADCs) and is utilized in both in vitro and in vivo studies for targeted cancer therapy research.